Dr. Marlowe is the Chief Scientific Officer and leads Research and Development efforts supporting Solid’s Freidrich’s Ataxia and cardiac pipeline programs.
Dr. Marlowe has served as the Chief Scientific Officer, Friedreich’s Ataxia and Cardiac Portfolio of Solid Biosciences, a gene therapy company, since December 2022. Dr. Marlowe served as the Chief Scientific Officer of AavantiBio from November 2021 to December 2022.
Prior to joining AavantiBio, Dr. Marlowe was the Vice President, beta-Thalassemia Program Lead at bluebird bio, Inc., a biotechnology company, from December 2020 to November 2021. Dr. Marlowe served as Vice President of Preclinical and Translational Development at bluebird from July 2019 to January 2021 and as Senior Director, Preclinical Development from August 2017 to July 2019. Prior to joining bluebird, Dr. Marlowe served as Director, Translational Safety Models, Discovery & Investigative Toxicology at Novartis Institutes for BioMedical Research, a pharmaceutical corporation, from January 2017 to August 2017. At Novartis Institutes, she also served as Global Head of Strategic Planning and Communication, Investigative Toxicology from June 2013 to August 2017, as Nonclinical Safety Project Team Member, Preclinical Safety from January 2009 to August 2017, and as a Group and Laboratory Head in Investigative Toxicology from January 2007 to December 2016. Dr. Marlowe holds a Ph.D. in Molecular Toxicology, with an emphasis in cellular and molecular mechanisms of carcinogenesis, from the Department of Environmental Health Sciences at the University of Cincinnati. She earned a Bachelor of Science in Zoology from Miami University.